RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancerIn a key mechanism of ADCs, once the antibody part of the drug binds to the target antigen expressed on the surface of tumor cells, the drug is absorbed into the tumor, where it releases the toxic payload to kill the cancer. Because Dato-DXd uses a very stable linker that barely breaks off and sets the payload free before entering the tumor, that internalization process becomes very important to the drug’s efficacy.
Because of the importance of this internalization process to the drug's efficacy, combination with pelareorep + paclitaxel followed by a checkpoint inhibitor (CPI) enhances the efficacy of the combined drug quartet.